4.3 Article

IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection

Journal

JOURNAL OF CYSTIC FIBROSIS
Volume 15, Issue 6, Pages 759-768

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2016.06.008

Keywords

Cystic fibrosis; Pseudomonas aeruginosa; Chronic infection; Interleukin-22; Mucosal immunity

Funding

  1. Wellcome Trust [094779]
  2. Academy of Medical Sciences (AMS) [AMS-SGCL6-Brodlie] Funding Source: researchfish
  3. Medical Research Council [MR/M008797/1, G0800419] Funding Source: researchfish
  4. MRC [MR/M008797/1, G0800419] Funding Source: UKRI

Ask authors/readers for more resources

Background: Interleukin (IL)-22 is a critical mediator of mucosal immunity and tissue regeneration, protecting against a number of respiratory pathogens. Whether IL-22 confers protection against chronic Pseudomonas aeruginosa (PA) infection in cystic fibrosis (CF) is unknown. Methods: Explanted CF lungs were examined for IL-22 production and immune-localization. A murine model of persistent pulmonary PA infection was used to examine production of IL-22 following infective challenge. The role of IL-22 was examined using IL-22 knockout (KO) animals. Results: IL-22 is produced within the adult CF lung and localizes to the airway epithelium. IL-22 is produced by murine pulmonary lymph node cells following lung infection. The absence of IL-22 resulted in no significant difference in acute mortality, bacterial burden, chronic infection rates, histological changes or neutrophilic inflammation in the chronic PA infection model. However, IL-22 KO animals lost less weight following infection. Conclusion: IL-22 is produced in the CF lung and in response to PA infection yet is dispensable in protection against chronic pulmonary P. aeruginosa infection in a murine model. However, we identified a novel role for the cytokine in promoting infection-related weight-loss, a significant prognostic factor in the CF population. (C) 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available